Q-omics provides the consensus-scored GOLGA8F profile across patient tissues and cancer cell-line models. GOLGA8F expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GOLGA8F is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, GOLGA8F RNA expression shows 6,490 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, BRCA, and STAD as cancer lineages where GOLGA8F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA8F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA8F survival associations across molecular data types. GOLGA8F RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA8F RNA expression–survival associations across cancer types. High GOLGA8F expression shows unfavorable associations in ACC, DLBC, UVM and KICH, but favorable associations in BLCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for GOLGA8F RNA expression.
This table summarizes GOLGA8F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA8F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA8F shows lower tumor expression in BRCA, THCA and KICH and higher tumor expression in KIRC. The BRCA box plot shows higher GOLGA8F RNA expression in normal versus tumor tissue (log2 FC = −0.008, t-test p < 0.001).
This table shows molecular features associated with GOLGA8F in patient tissues and cancer cell lines. In patient samples, GOLGA8F shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA8F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS.
